Addition of basal insulin to oral antidiabetic agents: A goal-directed approach to type 2 diabetes therapy

MedGenMed Medscape General Medicine

Volumn 8, Issue 4, 2006, Pages

  Kuritzky, Louis ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; AMINO ACID; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CREATININE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HAGEDORN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; ANTIDIABETIC AGENT; BASAL INSULIN; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES CONTROL; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; EDEMA; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAUNDICE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRACTICE GUIDELINE; REVIEW; TREATMENT OUTCOME; BLOOD; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MOTIVATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GOALS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33751232965     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29 (suppl 1):S4-S42. Abstract
2. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management-2002 Update. Endocr Pract. 2002;8(suppl 1):40-82. Abstract
3. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342. Abstract
4. Yki-Järvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-1136. Abstract
5. Vinik AI. Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus. Insulin. 2006;1:2-12.
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-1972. Abstract
7. Amaryl [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2005.
8. Micronase [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn Company; 2002.
9. Diabeta [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2004.
10. Glucotrol XL [prescribing information]. New York, NY: Pfizer Inc; 2003.
11. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994; 17:1460-1464. Abstract
12. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S. Longterm randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diabetes Care. 1994;17:45-49.
13. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-372. Abstract
14. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol. 2003;2:401-414. Abstract
15. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63:1747-1756. Abstract
16. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872. Abstract
17. Paolisso G, Amato L, Eccellente R, et al. Effect of metformin on food intake in obese subjects. Eur J Clin Invest. 1998;28:441-446. Abstract
18. Actos [package insert]. Lincolnshire, III: Takeda Pharmaceutical Company Limited; 2004.
19. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
20. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263. Abstract
21. Precose [prescribing information]. West Haven, Conn: Bayer Pharmaceuticals Corporation; 2003.
22. Glyset [prescribing information]. Kalamazoo, Mich: Pharmacia & Upjohn; 2004.
23. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10-16. Abstract
24. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336. Abstract
25. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study Group (UKPDS). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012. Abstract
26. Banerjee S, Sinharoy K, Singh AK. Oral hypoglycaemic agent failure. J Indian Med Assoc. 2002; 100:452-456. Abstract
27. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002; 113:3S-11S. Abstract
28. Dailey G. A timely transition to insulin: identifying type 2 diabetes patients failing oral therapy. Formulary. 2005;40:114-130.
29. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086. Abstract
30. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259. Abstract
31. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999; 130:389-396. Abstract
32. Bergenstal R, Johnson M, Whipple D, et al. Advantages of adding metformin to multiple dose insulin therapy in type 2 diabetes [abstract 0347]. Diabetes. 1998. Abstract 0347.
33. Rosenstock J, Einhom D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257. Abstract
34. American Association of Clinical Endocrinologists. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement, February 2, 2005. Available at: http://www.aace.com/pub/pdf/guidelines/ OutpatientimplementationPositionStatement.pdf. Accessed March 14, 2005.
35. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982;5:353-363. Abstract
36. Taskinen M-R, Sane T, Helve E, Karonen S-L, Nikkilä EA, Yki-Järvinen H. Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes. 1989;38:580-588. Abstract
37. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes. 1995;44:165-172. Abstract
38. Ryysy L, Yki-Järvinen H, Hänninen J. Simplifying treat to target - the LANMET study. In: Program and abstract of the 40th European Association for the Study of Diabetes Annual Meeting. September 7, 2004. September 5-9, 2004; Munich, Germany. Abstract 749.
39. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, Study Group. AT.LANTUS trial investigating treatment algorithms for insulin glargine (LANTUS®): results of the Type 2 Study [Abstract 1980-PO]. Diabetes. 2004;53 (suppl) 2:A473.
40. American Diabetes Association. Resource Guide: Insulin. Diabetes Forecast. 2006;(suppl):RG14-RG20.
41. Humulin® U Ultralente® and Humulin® L Lente® Insulins will no longer be available. Internet. 2005; Available at: http://www.lillydiabetes.com/pdf/Lente_Info_Sheet.pdf. Accessed O ctober 27, 2006.
42. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148. Abstract
43. Rosenstock J, Schwartz SL, Clark CMJ, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636. Abstract
44. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycernia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21:291-298. Abstract
45. Leahy JL. Intensive insulin therapy in type 1 diabetes mellitus. In: Leahy JL, Cefalu WT, eds. Insulin Therapy. New York, NY: Marcel Dekker, Inc., 2002: 87-112.
46. Campbell RK, White JR, Levien T, Baker D. Insulin glargine. Clin Ther. 2001;23:1938-1957. Abstract
47. Pieber TR, Plank J, Goerzer E, et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes [abstract]. Diabetes. 2003;51(supp 2):A53.
48. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999;16:332-338. Abstract
49. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care. 2001;24:296-301. Abstract
50. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201. Abstract
51. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274. Abstract
52. Vague P, Selam J-L, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycernia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590-596. Abstract
53. Kurtzhals P, Havelund S, Jonassen I, Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci. 1997;86:1365-1368. Abstract
54. BIRDSONG trial. Nederlands trial register: a comparison of once daily insulin detemir given pre-breakfast or bedtime, according to need, with bedtime insulin glargine in people with type 2 diabetes characterized by an asymmetric insulin requirement across the day and night. Available at: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=585. Accessed April 26, 2006.
55. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Diabetes Care. 1995;18:1113-1123. Abstract
56. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259-264. Abstract
57. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:182-188. Abstract
58. Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care. 1995;18:928-932. Abstract
59. Kelley DE, Bidot P, Freedman Z, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2056-2061. Abstract
60. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232. Abstract
61. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37:1020-1024. Abstract
62. Fritsche A, Schweitzer MA, Haring H-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003;138:952-959. Abstract
63. Tominaga M, Eguchi H, Manaka H, Iganashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920-924. Abstract
64. Prandin [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc.; 2003.
65. Starlix [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
66. Glucophage/Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2004.
67. Riomet [package insert]. Jacksonville, Fla: Ranbaxy Pharmaceuticals Inc.; 2003.